Defence, Security, Energy, Utilities, Finance, Pharmaceuticals
Home > Pharmaceuticals > UK

Advances in Cell Based Assays

Advances in 3D functional assays and high-content analysis to propel drug development and improve translation to the patient

10th November to 11th November 2015, London, United Kingdom

Overview

Open/Close

The latest study by VisionGain predicts that the cell-based assays market will reach $4.7 billion in 2016, as improvements in detection technology and sensitivity in drug screening will be among the major drivers in this market.

Drug screening is a costly process confronted with low productivity and challenges with using animals, which limits reproducible results for human relevance. Thus, efforts have been dedicated to developing cell-based high throughput screening (HTS) platforms that can provide more relevant in vivo biological information than biochemical assays and thus reduce the number of animal tests and accelerate the drug discovery process.


 

Today, cell-based assays are used in more than half of all high-throughput drug screenings for target validation and ADMET (absorption, distribution, metabolism, elimination and toxicity) in the early stage of drug discovery.

 

Benefits of Attending

Open/Close

Featured Speakers

Open/Close

Who Should Attend

Open/Close